4505 Emperor Boulevard
Suite 200
Durham, NC 27703
United States
919 859 1302
https://www.biocryst.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 536
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Jon P. Stonehouse | CEO, President & Executive Director | 1,23M | 647,14k | 1961 |
Ms. Alane P. Barnes | Senior VP, Chief Legal Officer & Corporate Secretary | 794,75k | N/D | 1966 |
Ms. Jinky Ang Rosselli | Chief Data & Insights Officer | N/D | N/D | N/D |
Mr. Philip George | Chief Strategy Officer | N/D | N/D | N/D |
Mr. Clayton Fletcher | Chief Business Development Officer | N/D | N/D | N/D |
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
L'ISS Governance QualityScore di BioCryst Pharmaceuticals, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 3; diritti degli azionisti: 8; retribuzione: 5.